Compare JBLU & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBLU | IMNM |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | JBLU | IMNM |
|---|---|---|
| Price | $4.91 | $22.32 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $4.76 | ★ $26.89 |
| AVG Volume (30 Days) | ★ 16.9M | 1.2M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,095,000,000.00 | $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.34 | $5.15 |
| 52 Week High | $8.31 | $20.80 |
| Indicator | JBLU | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 61.63 | 68.39 |
| Support Level | $4.67 | $18.81 |
| Resistance Level | $5.15 | $20.80 |
| Average True Range (ATR) | 0.22 | 1.45 |
| MACD | 0.05 | 0.12 |
| Stochastic Oscillator | 74.74 | 64.90 |
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.